Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Mesoblast Limited — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $24.84 (market cap $4.93B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: VanEck JP Morgan EM Local Currency Bond ETF is far larger — about 2.8× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 2,843,860). Which is the better fit depends on your goals — on Pluang, investors hold VanEck JP Morgan EM Local Currency Bond ETF for 38 Days and Mesoblast Limited for 15 Days on average.
| EMLC | MESO | |
|---|---|---|
Market Cap | $4.93B | $1.75B |
Volume | 2,843,860 | 239,027 |
Sector | Fixed Income | Health |
52-Week High | $26.59 | $20.96 |
52-Week Low | $24.53 | $13.19 |
Typical Hold Time | 38 Days | 15 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $24.78, showing minimal daily change. The technical outlook is bearish, with moving averages and ADX signaling a downtrend, while oscillators are neutral. Recent news highlights the ETF hitting a 52-week low amid a strengthening U.S. dollar, which pressures emerging market local currency bonds. No fundamental financial ratios are available in the provided data, limiting traditional valuation analysis.
The outlook remains cautious due to macroeconomic headwinds like dollar strength and potential Fed rate hikes. Risks include currency volatility and rising bond yields. Analyst sentiment appears bearish, with the ETF facing challenges in the near term, though diversification benefits in foreign bonds may offer long-term value if conditions stabilize.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
